GGrantIndex
← Leaderboards

Paul R Harmatz

University Of California San Francisco

Google Scholar ↗PubMed ↗ORCID ↗
$760,953
Attributed
$760,953
Total exposure
17
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$760,953 · 17

By mechanism

M01$760,953 · 17

Top collaborators

No co-investigators on record.

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationNutrition Related TagPatient Oriented ResearchDrug Screening /EvaluationLiver MetabolismIron PoisoningDiabetes Mellitus TherapyDietary SupplementsIatrogenic DiseaseSickle Cell AnemiaBiopsyDiet TherapyThalassemiaDiagnosis Quality /StandardAscorbateNutritionHyperglycemiaBlood TransfusionHealth Care Cost /FinancingInsulin Dependent Diabetes MellitusHemoglobinopathyHuman Tissue

Grant awards (40)

MPS II TKT$128,436
M01 · FY2005 · RR
MULTI CENTER, MULTI NATIONAL OPEN LABEL EXTENSION STUDY FOR MPS VI ASB-03-06$77,428
M01 · FY2005 · RR
NAT HISTORY IRON SCUID$43,686
M01 · FY2005 · RR
TCRN: HEPATITIS C CLINICAL TRIAL$22,164
M01 · FY2005 · RR
A PHASE II OPEN-LABEL CLINICAL STUDY OF EFFICACY AND SAFETY OF RECOMBINANT H$11,743
M01 · FY2005 · RR
PHASE II MPS$5,871
M01 · FY2005 · RR
PHASE III MPS VI$3,779
M01 · FY2005 · RR
VALIDATION OF BIOSUSCEPTOMETRY AS A NON-INVASIVE TECHNIQUE FOR ASSESSMENT OF$1,101
M01 · FY2005 · RR
MPS Phase III$115,697
M01 · FY2004 · RR
MPS II$92,252
M01 · FY2004 · RR
NAT HISTORY IRON SQUID$83,306
M01 · FY2004 · RR
TCRN: Hepatitis C Clinical Trial$27,352
M01 · FY2004 · RR
A Phase II Open-Label Clinical study of efficacy and safety of Recombinant H...$21,422
M01 · FY2004 · RR
HORMONES CARETAKERS$16,364
M01 · FY2004 · RR
BIOFRONTIERS$11,722
M01 · FY2004 · RR
CHROMIUM PICOLINATE AND BIOTIN SUPPLEMENTATION TO DIMINISH GLYCATION IN CHILD...$10,196
M01 · FY2004 · RR
PHASE II MPS$9,303
M01 · FY2004 · RR
Validation of biosusceptometry as a non-invasive technique for assessment of...$6,625
M01 · FY2004 · RR
CELL MECH$3,451
M01 · FY2004 · RR
VARIABILITY IN HEPATIC IRON CONCENTRATION FROM NEEDLE BIOPSY SPECIMEN$0
M01 · FY2002 · RR
VITAMIN C SUPPLEMENTATION IN DIABETIC CHILDREN$0
M01 · FY2002 · RR
INTENSIVE NUTRITION THERAPY IN PATIENTS WITH SICKLE CELL ANEMIA$0
M01 · FY2002 · RR
VITAMIN C SUPPLEMENTATION IN DIABETIC CHILDREN$0
M01 · FY2001 · RR
VARIABILITY IN HEPATIC IRON CONCENTRATION FROM NEEDLE BIOPSY SPECIMEN$0
M01 · FY2001 · RR
INTENSIVE NUTRITION THERAPY IN PATIENTS WITH SICKLE CELL ANEMIA$0
M01 · FY2001 · RR
INTENSIVE NUTRITION THERAPY IN PATIENTS WITH SICKLE CELL ANEMIA$25,799
M01 · FY2000 · RR
VITAMIN C SUPPLEMENTATION IN DIABETIC CHILDREN$25,799
M01 · FY2000 · RR
VARIABILITY IN HEPATIC IRON CONCENTRATION FROM NEEDLE BIOPSY SPECIMEN$17,457
M01 · FY2000 · RR
RED BLOOD CELL TRANSFUSION NEED IN THALASSEMIA USING CO$0
M01 · FY2000 · RR
VARIABILITY IN HEPATIC IRON CONCENTRATION FROM NEEDLE BIOPSY SPECIMEN$0
M01 · FY2000 · RR
VARIABILITY IN HEPATIC IRON CONCENTRATION FROM NEEDLE BIOPSY SPECIMEN$0
M01 · FY2000 · RR
INTENSIVE NUTRITION THERAPY IN PATIENTS WITH SICKLE CELL ANEMIA$0
M01 · FY2000 · RR
INTENSIVE NUTRITION THERAPY IN PATIENTS WITH SICKLE CELL ANEMIA$0
M01 · FY2000 · RR
VITAMIN C SUPPLEMENTATION IN DIABETIC CHILDREN$0
M01 · FY2000 · RR
VITAMIN C SUPPLEMENTATION IN DIABETIC CHILDREN$0
M01 · FY2000 · RR
LAMIVUDINE TREATMENT IN KIDS WITH CHRONIC HEPATITIS B$0
M01 · FY2000 · RR
LAMIVUDINE TREATMENT IN KIDS WITH CHRONIC HEPATITIS B$0
M01 · FY2000 · RR
LAMIVUDINE TREATMENT IN KIDS WITH CHRONIC HEPATITIS B$0
M01 · FY2000 · RR
RED BLOOD CELL TRANSFUSION NEED IN THALASSEMIA USING CO$0
M01 · FY2000 · RR
RED BLOOD CELL TRANSFUSION NEED IN THALASSEMIA USING CO$0
M01 · FY2000 · RR